

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Health Technology Appraisal**

**Review of TA No.64 Growth hormone deficiency (adults) - human growth hormone**

**Provisional matrix of consultees and commentators**

| <b>Consultees</b>   | <b>Commentators (no right to submit or appeal)</b>   |
|---|--|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Eli Lilly (somatropin)</li> <li>• Ferring Pharmaceuticals (somatropin)</li> <li>• Ipsen (somatropin)</li> <li>• Merck Serono (somatropin)</li> <li>• Novo Nordisk (somatropin)</li> <li>• Pfizer (somatropin)</li> <li>• Sandoz (somatropin)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Equalities National Council</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• Pituitary Foundation</li> <li>• Prader-Willi Syndrome Association (UK)</li> <li>• Restricted Growth Association</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Turner Syndrome Support Society</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Metabolic and Endocrine Disorders Group</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• United Kingdom Clinical Research Network</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment</li> </ul> |

| Consultees   | Commentators (no right to submit or appeal)   |
|--|---|
| <ul style="list-style-type: none"> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• Society for Endocrinology</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Hull Teaching PCT</li> <li>• Luton Teaching PCT</li> <li>• Welsh Assembly Government</li> </ul> | <p>Programme</p> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• Tbc</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> |

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

